- White House Plans to Freeze Spending to Cut Deficit
- Week Ahead: Investors Go for Quality, Assess Recovery
- Hedge Fund Billionaire Paulson Reports New Citi Stake
- Cramer: 5 Earnings Reports to Watch Next Week
- Court Rejects 'Clawbacks' for Alleged Stanford Victims
- Cities With the Most Home Price Reductions
- Tax Credit Sparking First-Time Home Sales: Realtors
- Investors Cut Back US Stocks for Bigger Growth Abroad
- This Year's Biggest Thanksgiving Leftover: Cash
- U.S. Stocks Rally for the Second Straight Week
- Dollar is Not Plunging—So 'Calm Down': Market Strategist
- Strategists Say Markets Have More Upside — But How Much?
- Hirschhorn: Risk-Averse Traders
- Roginsky: A Funny Thing Happened on the Way to Financial Reform
- This Year's Biggest Thanksgiving Leftover: Cash
- TV Series Inks Unique Deal For Fight
- First Time Buyers Rescue Housing: Realtors
- Dollar General Trades Higher After Its IPO
MOST SHARED
- Today's Market Action
- CNBC Video: Warren Buffett & Bill Gates - Keeping American Great
- Microsoft's Bill Gates Praises Apple's Steve Jobs For 'Saving the Company'
- Has Twitter's Finest Hours (Seconds) Come and Gone?
- Israel Going Green
- Low Interest Rate Investing
- CNBC TRANSCRIPT: Warren Buffett & Bill Gates - Keeping America Great
- Inside Wal-Mart's Acai Berry Juice Maker
- China's Role as Lender Alters Dynamics for United States
Text Size 
Bowing to pressure from an Icos [ICOS
Loading...
()
] shareholder, Eli Lilly [LLY
Loading...
()
] said it has increased its offer for the biotechnology company to $2.3 billion from an earlier bid of $2.1 billion.
The revised price of $34 a share follows objections from HealthCor, a big Icos shareholder, to the earlier $32-a-share offer. HealthCor argued that Icos was worth more than $40 a share.
Lilly, which agreed in October to acquire Icos to gain full ownership of the erectile dysfunction drug Cialis, said its latest offer is its "best and final offer."
"We are confident that Icos shareholders will recognize the substantial value and the certainty that Lilly is offering," Sidney Taurel, Lilly's chief executive officer, said in a statement.
Indianapolis-based Lilly, which currently markets Cialis with Icos through a joint venture, said the boards of both companies have unanimously approved the new offer.
Lilly is eager to take advantage of a revival in the erectile dysfunction market, which was hurt last year by concerns that drugs to treat the condition, including Pfizer [PFE
Loading...
()
] Viagra, could cause blindness.
News of the increased Icos bid comes a day after a report on the New York Times' Web site that Eli Lilly downplayed risks associated with Zyprexa, a drug it makes for the treatment of schizophrenia. Zyprexa is Eli Lilly's best-selling product, the Times said.
Print
Email
- Warren Buffett and Bill Gates spoke to Columbia students, and Buffett made the students a startling offer.
- For the chief of cable company Comcast, growth has been about making deals – generally very large deals.
- Some companies may start using insurance to shift carbon risk from their balance sheets to maybe... yours?
- The president and founder of Genesis Today wants to improve America’s health, and thinks Wal-Mart can help.
- Switzerland's privacy watchdog is taking legal action to force Google to make changes to its Street View service.
- A wealthy, distracted Texas driver crashed his million-dollar Bugatti Veyron sports car into a salt marsh, say police.
Data is a real-time snapshot *Data is delayed at least 15 minutes